Last updated: May 15, 2007
Sponsor: GE Healthcare
Overall Status: Completed
Phase
3
Condition
Vascular Dementia
Vascular Diseases
Parkinson's Disease
Treatment
N/AClinical Study ID
NCT00209456
PDT301
Ages 55-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subjects must be adults between 55 to 90 years of age with an established diagnosisfor dementia in accordance with DSM-IV criteria and have to fulfil at least one of thefollowing: The ICC criteria for probable and possible DLB, the National Institute ofNeurological and Communicative Disorders and Stroke and Alzheimer Disease and RelatedDisorders Association (NINCDS-ADRDA) for Alzheimer’s Disease (AD), or the NationalInstitute of Neurological and Communicative Disorders and Association InternationalePour la Recherche et l’Enseignement en Neurosciences (NINCS-AIREN) for VascularDementia (VaD).
Exclusion
Exclusion Criteria:
Subjects are not eligible if they have a Mini Mental State Examination (MMSE) score of <10 and use medication known or suspected to interact with the striatal uptake DaTSCANto the dopamine transporter.
Furthermore subjects are not eligible if they were diagnosed with idiopathicParkinson’s Disease (PD), with persistent severe depression, normal pressurehydrocephalus, multiple system atrophy, cortico-basal degeneration or Huntington’sChorea Disease.
Study Design
Total Participants: 326
Study Start date:
November 01, 2003
Estimated Completion Date:
Study Description
Connect with a study center
Amersham Buchler GmbH Co. KG
Ismaning,
GermanySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.